
Opinion|Videos|February 14, 2025
Ensifentrine (ENHANCE Trials) in COPD
Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Ensifentrine is recommended in the 2025 GOLD Report as a bronchodilator to improve dyspnea. Ensifentrine is also suggested as a potential anti-inflammatory therapy in stable COPD.
- What were the main patient eligibility criteria and clinical outcomes in the ENHANCE trials?
- How do you anticipate that ensifentrine will be used in clinical practice (ie, monotherapy, add-on, both)?
Advertisement
Related to this article

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

